OTC: IPSEF - Ipsen S.A.

Rentabilität für sechs Monate: +2.5%
Dividendenrendite: +0.96%
Sektor: Healthcare

Aktionsplan Ipsen S.A.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Ipsen S.A.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma.

weitere details
The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета eur
Див.доход ао 0.9639
Дивиденд ао 1.16
Сайт https://www.ipsen.com
Цена ао 120.55
Preisänderung pro Tag: 0% (120.55)
Preisänderung pro Woche: 0% (120.55)
Preisänderung pro Monat: 0% (120.55)
Preisänderung über 3 Monate: -3.84% (125.37)
Preisänderung über sechs Monate: +2.5% (117.61)
Preisänderung pro Jahr: +2.51% (117.6)
Preisänderung seit Jahresbeginn: -3.84% (125.37)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 2.63 6
P/BV 2.15 7
P/E 12.77 8
EV/EBITDA 8.63 8
Gesamt: 7.88

Effizienz

Name Bedeutung Grad
ROA, % 10.19 4
ROE, % 16.85 5
Gesamt: 5

Dividenden

Name Bedeutung Grad
Div yield, % 0.9639 2.4
DSI 0.8571 8.57
Gesamt: 2.86

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0.4137 10
Gesamt: 9.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 22.79 4
Rentabilität Ebitda, % 4.08 1
Rentabilität EPS, % -1246.72 0
Gesamt: 2.8
Weitere Details



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. David Loew MD, CEO & Director 2.41M 1967 (58 Jahre)
Mr. Aymeric Le Chatelier Executive VP & CFO 792.51k 1969 (56 Jahre)
Dr. Aidan Murphy Ph.D. Executive VP and Head of Technical Operations N/A 1966 (59 Jahre)
Mr. Craig Marks Vice-President of Investor Relations N/A
Mr. Francois Garnier Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer N/A 1962 (63 Jahr)
Mr. Regis Mulot Executive VP & Chief Human Resources Officer N/A 1966 (59 Jahre)
Ms. Dominique Bery Head of Nordics & Baltics N/A 1971 (54 Jahr)
Mr. Bartosz Bednarz D.D.S. Executive VP and Head of Global Product & Portfolio Strategy N/A
Mr. Philippe Lopes-Fernandes CBO Executive VP & Chief Business Officer N/A
Dr. James Levine M.D., Ph.D. President of Fondation Ipsen

Adresse: France, Boulogne-Billancourt, 65 quai Georges Gorse - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.ipsen.com